$BICX
BioCorRx Inc. Stock $bicx

$bicx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000147793223002039 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$40.44K	$82.88K	$213.8K
YoY Change	97.1%	508.96%	342.99%
Cost Of Revenue	$8.676K	$8.680K	$18.95K
YoY Change	463.38%	257.2%	222.16%
Gross Profit	$31.77K	$74.20K	$194.9K
YoY Change	67.37%	563.69%	359.76%
Gross Profit Margin	78.55%	89.53%	91.14%
Selling, General & Admin	$796.1K	$717.1K	$3.410M
YoY Change	-15.22%	-34.97%	-8.85%
% of Gross Profit	2505.98%	966.42%	1749.48%
Research & Development	$237.4K	$536.1K	$1.459M
YoY Change	19.98%	128.69%	-9.12%
% of Gross Profit	747.3%	722.51%	748.84%
Depreciation & Amortization	$6.370K	$6.860K	$27.45K
YoY Change	-3.01%	0.0%	-1.18%
% of Gross Profit	20.05%	9.25%	14.08%
Operating Expenses	$1.097M	$1.260M	$4.912M
YoY Change	-4.23%	-6.25%	-11.63%
Operating Profit	-$1.056M	-$1.186M	-$4.698M
YoY Change	-6.08%	-11.03%	-14.74%
Interest Expense	$26.04K	-$194.4K	$151.0K
YoY Change	-84.39%	11.5%	-126.69%
% of Operating Profit
Other Income/Expense, Net	$45.73K	$217.3K	$321.2K
YoY Change	-74.55%	-28.95%	7.24%
Pretax Income	-$1.011M	-$1.163M	-$4.377M
YoY Change	6.94%	-3.2%	-16.0%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.011M	-$1.160M	-$4.377M
YoY Change	6.94%	-3.42%	-16.0%
Net Earnings / Revenue	-2498.85%	-1399.36%	-2046.77%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.13	-$0.15	-$0.61
COMMON SHARES
Basic Shares Outstanding	7.737M shares	7.628M shares
Diluted Shares Outstanding	1.799M shares		1.448M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$203.7K	$68.62K	$68.62K
YoY Change	215.55%	-20.06%	-20.06%
Cash & Equivalents	$203.7K	$68.62K
Short-Term Investments
Other Short-Term Assets	$56.75K	$82.77K	$82.77K
YoY Change	-81.28%	-2.2%	-2.2%
Inventory
Prepaid Expenses	$56.75K	$82.77K
Receivables	$83.99K	$165.5K	$165.5K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$344.4K	$316.9K	$316.9K
YoY Change	-41.37%	38.8%	38.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$70.20K	$76.57K	$347.0K
YoY Change	-27.08%	-25.54%	-28.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$44.52K	$44.52K	$44.52K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$364.7K	$449.7K	$449.7K
YoY Change	-34.53%	-23.99%	-24.0%
TOTAL ASSETS
Total Short-Term Assets	$344.4K	$316.9K	$316.9K
Total Long-Term Assets	$364.7K	$449.7K	$449.7K
Total Assets	$709.2K	$766.6K	$766.6K
YoY Change	-38.04%	-6.51%	-6.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.190M	$2.013M	$2.013M
YoY Change	144.44%	104.06%	13.3%
Accrued Expenses	$2.100M	$2.029M	$2.029M
YoY Change	32.13%	32.5%	32.5%
Deferred Revenue
YoY Change
Short-Term Debt	$1.538M	$0.00	$1.288M
YoY Change	52.08%	-100.0%	27.35%
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$5.853M	$5.364M	$5.364M
YoY Change	32.64%	22.28%	22.28%
LONG-TERM LIABILITIES
Long-Term Debt	$73.51K	$73.85K	$73.85K
YoY Change	-61.39%	-57.6%	-57.6%
Other Long-Term Liabilities	$3.610M	$3.531M	$3.531M
YoY Change	9.55%	9.62%	9.62%
Total Long-Term Liabilities	$3.683M	$3.605M	$3.605M
YoY Change	5.67%	6.17%	6.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.853M	$5.364M	$5.364M
Total Long-Term Liabilities	$3.683M	$3.605M	$3.605M
Total Liabilities	$9.536M	$8.968M	$8.843M
YoY Change	22.58%	15.25%	15.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$75.35M	-$74.34M
YoY Change		6.24%
Common Stock	$8.103K	$7.719K
YoY Change		15.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$8.701M	-$8.202M	-$8.076M
YoY Change
Total Liabilities & Shareholders Equity	$709.2K	$766.6K	$766.6K
YoY Change	-38.04%	-6.51%	-6.51%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.011M	-$1.160M	-$4.377M
YoY Change	6.94%	-3.42%	-16.0%
Depreciation, Depletion And Amortization	$6.370K	$6.860K	$27.45K
YoY Change	-3.01%	0.0%	-1.18%
Cash From Operating Activities	-$397.4K	-$449.6K	-$2.042M
YoY Change	-54.47%	-30.58%	-42.28%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.250M
YoY Change			-44.44%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$532.4K	454.7K	$2.025M
YoY Change	-46.76%		-34.3%
NET CHANGE
Cash From Operating Activities	-$397.4K	-449.6K	-$2.042M
Cash From Investing Activities		0.000	$0.00
Cash From Financing Activities	$532.4K	454.7K	$2.025M
Net Change In Cash	$135.1K	5.090K	-$17.22K
YoY Change	6.08%	-100.77%	-96.6%
FREE CASH FLOW
Cash From Operating Activities	-$397.4K	-$449.6K	-$2.042M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$449.6K	-$2.042M
YoY Change		-29.27%	-43.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4697995	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-5510107	usd
CY2021Q4	us-gaap	Cash Cash	85838	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001443863
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6698968	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7718636	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	600000	shares
CY2021Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	848559	shares
CY2021	bicx	Outstanding At Ending OutstandingAtEnding	P4Y10M24D
CY2022	bicx	Term Of Options TermOfOptions	P3Y
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Entity File Number EntityFileNumber	000-54208
CY2022	dei	Entity Registrant Name EntityRegistrantName	BioCorRx Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0967447
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2390 East Orangewood Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 500
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Anaheim
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92806
CY2022	dei	City Area Code CityAreaCode	714
CY2022	dei	Local Phone Number LocalPhoneNumber	462-4880
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q4	bicx	Debt Discount On Notes Payable Related Parties DebtDiscountOnNotesPayableRelatedParties	0	usd
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	12386815	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7737418	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Friedman LLP
CY2022	dei	Auditor Location AuditorLocation	Marlton, New Jersey
CY2022Q4	us-gaap	Cash Cash	68615	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	35378	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1500	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	44520	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	44520	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1077088	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1014892	usd
CY2022Q4	bicx	Debt Discount On Notes Payable DebtDiscountOnNotesPayable	23878	usd
CY2021Q4	bicx	Debt Discount On Notes Payable DebtDiscountOnNotesPayable	0	usd
CY2022Q4	bicx	Debt Discount On Notes Payable Related Parties DebtDiscountOnNotesPayableRelatedParties	49473	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	990637	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	790110	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	31580	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	99860	usd
CY2022Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	73850	usd
CY2021Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	74300	usd
CY2022Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	5376790	usd
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	5854226	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	3345310	usd
CY2021Q4	us-gaap	Contractual Obligation ContractualObligation	2867874	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	181328	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	315672	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4045	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	37301	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8968325	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7781451	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	600000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7718636	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7719	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6699	usd
CY2022Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	100000	usd
CY2021Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	100000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66130296	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	62994739	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-74336105	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-69966692	usd
CY2022Q4	bicx	Total Deficit Attributable To Biocorrx Inc TotalDeficitAttributableToBiocorrxInc	-8076474	usd
CY2021Q4	bicx	Total Deficit Attributable To Biocorrx Inc TotalDeficitAttributableToBiocorrxInc	-6843638	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-125257	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-117838	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8201731	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6961476	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	766594	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	819975	usd
CY2022	us-gaap	Revenues Revenues	213841	usd
CY2021	us-gaap	Revenues Revenues	48272	usd
CY2022	bicx	Cost Of Implants And Other Costs CostOfImplantsAndOtherCosts	15279	usd
CY2021	bicx	Cost Of Implants And Other Costs CostOfImplantsAndOtherCosts	5881	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27450	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	64328	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4911836	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	5558379	usd
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	935806	usd
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	546260	usd
CY2022	us-gaap	Interest Expense InterestExpense	150969	usd
CY2021	us-gaap	Interest Expense InterestExpense	19424	usd
CY2022	bicx	Loss On Settlement Of Debt LossOnSettlementOfDebt	198939	usd
CY2021	bicx	Loss On Settlement Of Debt LossOnSettlementOfDebt	0	usd
CY2022	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	322000	usd
CY2021	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	usd
CY2022	bicx	Grant Income GrantIncome	1789496	usd
CY2021	bicx	Grant Income GrantIncome	835924	usd
CY2022	us-gaap	Other Income OtherIncome	139381	usd
CY2021	us-gaap	Other Income OtherIncome	29229	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	321163	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	299469	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4376832	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5210638	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4376832	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5210638	usd
CY2022	us-gaap	Noninterest Income NoninterestIncome	7419	usd
CY2021	us-gaap	Noninterest Income NoninterestIncome	2384	usd
CY2022	bicx	Dividend Attributable To Down Round Feature Of Warrants DividendAttributableToDownRoundFeatureOfWarrants	0	usd
CY2021	bicx	Dividend Attributable To Down Round Feature Of Warrants DividendAttributableToDownRoundFeatureOfWarrants	70127	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-4369413	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-5278381	usd
CY2022	bicx	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.61
CY2021	bicx	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.81
CY2022	bicx	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	7198312	shares
CY2021	bicx	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	6491067	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-4210353	usd
CY2021	bicx	Common Stock Issued In Connection With Subscription Agreement Amount CommonStockIssuedInConnectionWithSubscriptionAgreementAmount	2250000	usd
CY2021	bicx	Common Stock Issued In Connection With Exercise Of Warrants Amount CommonStockIssuedInConnectionWithExerciseOfWarrantsAmount	0	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	200800	usd
CY2021	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	8715	usd
CY2021	bicx	Recognition Of Down Round Feature In Connection With Exercise Of Warrants RecognitionOfDownRoundFeatureInConnectionWithExerciseOfWarrants	0	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5210638	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6961476	usd
CY2022	bicx	Common Stock Issued In Connection With Subscription Agreement Amount CommonStockIssuedInConnectionWithSubscriptionAgreementAmount	1250000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	243430	usd
CY2022	bicx	Warrants Issued In Connection With Loan Default WarrantsIssuedInConnectionWithLoanDefault	86821	usd
CY2022	bicx	Warrants Issued In Connection With Loan Default Related Party WarrantsIssuedInConnectionWithLoanDefaultRelatedParty	214975	usd
CY2022	bicx	Common Stock Issued In Connection With Conversion Of Promissory Notes And Accounts Payable Amount CommonStockIssuedInConnectionWithConversionOfPromissoryNotesAndAccountsPayableAmount	1062632	usd
CY2022	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes Amount CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotesAmount	167640	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	111079	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4376832	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8201731	usd
CY2022	us-gaap	Profit Loss ProfitLoss	4376832	usd
CY2021	us-gaap	Profit Loss ProfitLoss	5210638	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27450	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	64328	usd
CY2022	bicx	Amortization Of Discount On Royalty Obligation AmortizationOfDiscountOnRoyaltyObligation	477436	usd
CY2021	bicx	Amortization Of Discount On Royalty Obligation AmortizationOfDiscountOnRoyaltyObligation	477436	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	17399	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	141480	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	114515	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	104615	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	354509	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	209515	usd
CY2022	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	322000	usd
CY2021	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	usd
CY2022	bicx	Loss On Settlement Of Debt LossOnSettlementOfDebt	198939	usd
CY2021	bicx	Loss On Settlement Of Debt LossOnSettlementOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	133424	usd
CY2022	bicx	Noncash Interest For Debt Discount NoncashInterestForDebtDiscount	378686	usd
CY2021	bicx	Noncash Interest For Debt Discount NoncashInterestForDebtDiscount	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	33878	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-73793	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	168520	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1864	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	72864	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	838071	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	698631	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-119734	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-106290	usd
CY2022	bicx	Increase Decrease In Deferred Revenue Grant IncreaseDecreaseInDeferredRevenueGrant	0	usd
CY2021	bicx	Increase Decrease In Deferred Revenue Grant IncreaseDecreaseInDeferredRevenueGrant	-65560	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-34981	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2041773	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2017	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	47980	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49997	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1250000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2250000	usd
CY2022	bicx	Payment To Economic Injury Disaster Loan PaymentToEconomicInjuryDisasterLoan	450	usd
CY2021	bicx	Payment To Economic Injury Disaster Loan PaymentToEconomicInjuryDisasterLoan	0	usd
CY2022	us-gaap	Proceeds From Loans ProceedsFromLoans	0	usd
CY2021	us-gaap	Proceeds From Loans ProceedsFromLoans	131440	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100000	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	200000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	675000	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2024550	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3081440	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-17223	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-506215	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85838	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	592053	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68615	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85838	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotes	167641	usd
CY2022	bicx	Common Stock Issued In Connection With Conversion Of Promissory Notes And Accounts Payable CommonStockIssuedInConnectionWithConversionOfPromissoryNotesAndAccountsPayable	1062632	usd
CY2021	bicx	Common Stock Issued In Connection With Conversion Of Promissory Notes And Accounts Payable CommonStockIssuedInConnectionWithConversionOfPromissoryNotesAndAccountsPayable	0	usd
CY2022	bicx	Recognition Of Down Round Feature RecognitionOfDownRoundFeature	0	usd
CY2021	bicx	Recognition Of Down Round Feature RecognitionOfDownRoundFeature	70127	usd
CY2022	bicx	Common Stock Issued In Connection With Exercise Of Warrants CommonStockIssuedInConnectionWithExerciseOfWarrants	0	usd
CY2021	bicx	Common Stock Issued In Connection With Exercise Of Warrants CommonStockIssuedInConnectionWithExerciseOfWarrants	47	usd
CY2022	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	14360	usd
CY2021	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	1500	usd
CY2022	bicx	Project Support Income ProjectSupportIncome	150578	usd
CY2021	bicx	Project Support Income ProjectSupportIncome	0	usd
CY2022	us-gaap	Investment Company Dividend Distribution InvestmentCompanyDividendDistribution	37293	usd
CY2021	us-gaap	Investment Company Dividend Distribution InvestmentCompanyDividendDistribution	35481	usd
CY2022	bicx	Membership Program Fees MembershipProgramFees	11610	usd
CY2021	bicx	Membership Program Fees MembershipProgramFees	11291	usd
CY2022	us-gaap	Revenues Revenues	213841	usd
CY2021	us-gaap	Revenues Revenues	48272	usd
CY2021Q4	bicx	Deferred Revenue Short Term DeferredRevenueShortTerm	34981	usd
CY2021Q4	bicx	Deferred Revenue Long Term DeferredRevenueLongTerm	37301	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	72282	usd
CY2021Q4	bicx	Net Sales Recognized NetSalesRecognized	-34981	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	37301	usd
CY2022Q4	bicx	Deferred Revenue Short Term DeferredRevenueShortTerm	33256	usd
CY2022Q4	bicx	Deferred Revenue Long Term DeferredRevenueLongTerm	4045	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3680	usd
CY2022Q4	bicx	Prepaid Subscription Services PrepaidSubscriptionServices	49901	usd
CY2021Q4	bicx	Prepaid Subscription Services PrepaidSubscriptionServices	79455	usd
CY2022Q4	bicx	Prepaid Research And Development PrepaidResearchAndDevelopment	7480	usd
CY2021Q4	bicx	Prepaid Research And Development PrepaidResearchAndDevelopment	0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include assumptions used in the fair value of stock-based compensation, the fair value of other equity and debt instruments.</p>
CY2022Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	141480	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	325965	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	426917	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	21100	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1494	usd
CY2022Q4	us-gaap	Collateralized Financings CollateralizedFinancings	47980	usd
CY2022	bicx	Shares Underlying Options Outstanding SharesUnderlyingOptionsOutstanding	874058	usd
CY2021	bicx	Shares Underlying Options Outstanding SharesUnderlyingOptionsOutstanding	815351	usd
CY2022	bicx	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	333855	shares
CY2022	bicx	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	240000	shares
CY2021	bicx	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	240000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1447913	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1055351	shares
CY2019Q1	bicx	Funding During First Year FundingDuringFirstYear	2842430	usd
CY2019Q1	bicx	Funding During Second Year FundingDuringSecondYear	2831838	usd
CY2019Q1	bicx	Grant Funding During The Third Year GrantFundingDuringTheThirdYear	3453367	usd
CY2019Q1	bicx	Grant Additional Funding During The Third Year GrantAdditionalFundingDuringTheThirdYear	99431	usd
CY2022Q4	bicx	Grant Receivables GrantReceivables	122652	usd
CY2021Q4	bicx	Grant Receivables GrantReceivables	56359	usd
CY2022	bicx	Grant Income GrantIncome	1789496	usd
CY2021	bicx	Grant Income GrantIncome	835924	usd
CY2022Q4	us-gaap	Direct To Television Film Costs Development DirectToTelevisionFilmCostsDevelopment	253208	usd
CY2021Q4	us-gaap	Direct To Television Film Costs Development DirectToTelevisionFilmCostsDevelopment	272681	usd
CY2022	bicx	Grant Funding Indirect Cost GrantFundingIndirectCost	516218	usd
CY2022Q4	bicx	Allocation Of Remaining Fa Indirect Cost AllocationOfRemainingFAIndirectCost	9671	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1459458	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1605907	usd
CY2022	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.50	pure
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	82765	usd
CY2022	bicx	Royalty Obligations Net Policy Textblock RoyaltyObligationsNetPolicyTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued. In order to record the discount of the liability, the Company fair valued the royalty and the difference between fair value of the royalty obligation and the gross projected future payments was $7,171,200 and was recorded as non-cash interest expense over the life of the liability and offset to additional paid in capital at inception.</p>
CY2022	bicx	Royalty Obligations Description RoyaltyObligationsDescription	The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years
CY2022	us-gaap	Royalty Expense RoyaltyExpense	7171200	usd
CY2022Q4	us-gaap	Cash Cash	68615	usd
CY2022Q4	bicx	Working Capital Deficiency WorkingCapitalDeficiency	-5046882	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2041773	usd
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	340505	shares
CY2022	bicx	Gross Proceeds GrossProceeds	1250000	usd
CY2022Q4	bicx	Due Amount DueAmount	75000	usd
CY2022	bicx	Advance Received AdvanceReceived	75000	usd
CY2022	bicx	Exchange Agreement Description ExchangeAgreementDescription	the Company entered into an Exchange Agreement (the “Joseph Exchange Agreement”) with Joseph J Galligan, a member of the Company’s Board, pursuant to which Mr. Joseph Galligan agreed to exchange of the promissory note then outstanding of $125,000, the accrued interest on the promissory note of $46,548, and the unpaid service fees of $175,090 into the Company’s 194,740 shares of common stock
CY2022	bicx	Schedule Of Prepaid Expenses Table Textblock ScheduleOfPrepaidExpensesTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid insurance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,284</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,680</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid subscription services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,901</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,455</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,480</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Other prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,494</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">82,765</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">84,629</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	4284	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	84629	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	194551	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	194551	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	117979	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	91708	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	76572	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	102843	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	500333	usd
CY2022Q4	bicx	Total Lease Liability TotalLeaseLiability	315671	usd
CY2021Q4	bicx	Total Lease Liability TotalLeaseLiability	435405	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134343	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	119733	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	181328	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	315672	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	154771	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	159420	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	31690	usd
CY2022Q4	bicx	Present Value Discount PresentValueDiscount	-30210	usd
CY2022Q4	bicx	Lease Liability LeaseLiability	315671	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	144978	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	144057	usd
CY2022	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	144978	usd
CY2021	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	144057	usd
CY2022	bicx	Total Lease Expense TotalLeaseExpense	150196	usd
CY2021	bicx	Total Lease Expense TotalLeaseExpense	143447	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1169	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1169	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1169	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1169	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	5530	usd
CY2022Q4	bicx	Total Future Amortization Of The Patents TotalFutureAmortizationOfThePatents	10206	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2013250	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1776905	usd
CY2022Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	1206753	usd
CY2021Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	1153773	usd
CY2022Q4	bicx	Interest Payable On Notes Payable Related Parties InterestPayableOnNotesPayableRelatedParties	332567	usd
CY2021Q4	bicx	Interest Payable On Notes Payable Related Parties InterestPayableOnNotesPayableRelatedParties	224592	usd
CY2022Q4	bicx	Deferred Insurance DeferredInsurance	0	usd
CY2021Q4	bicx	Deferred Insurance DeferredInsurance	2561	usd
CY2022Q4	bicx	Accrual Of Loss On Contingency AccrualOfLossOnContingency	322000	usd
CY2021Q4	bicx	Accrual Of Loss On Contingency AccrualOfLossOnContingency	0	usd
CY2022Q4	bicx	Interest Payable On Eidl Loan InterestPayableOnEidlLoan	5860	usd
CY2021Q4	bicx	Interest Payable On Eidl Loan InterestPayableOnEidlLoan	4076	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	0	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	983	usd
CY2022Q4	bicx	Accrued Expenses AccruedExpenses	27524	usd
CY2021Q4	bicx	Accrued Expenses AccruedExpenses	25670	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3907954	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3188560	usd
CY2022Q4	bicx	Advances From A Third Party AdvancesFromAThirdParty	21480	usd
CY2022Q4	bicx	Advances From A Third Party AdvancesFromAThirdParty	21480	usd
CY2021Q4	bicx	Advances From A Third Party AdvancesFromAThirdParty	21480	usd
CY2022Q4	bicx	Promissory Note Payable PromissoryNotePayable	200000	usd
CY2021Q4	bicx	Promissory Note Payable PromissoryNotePayable	200000	usd
CY2022Q4	us-gaap	Other Notes Payable OtherNotesPayable	76122	usd
CY2021Q4	us-gaap	Other Notes Payable OtherNotesPayable	0	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	297602	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	221480	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	1000	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	1034	usd
CY2022Q4	bicx	Accumulated Interest On Eidl Loan AccumulatedInterestOnEidlLoan	5860	usd
CY2021Q4	bicx	Accumulated Interest On Eidl Loan AccumulatedInterestOnEidlLoan	4076	usd
CY2022	bicx	Schedule Of Future Principle Payments ScheduleOfFuturePrinciplePayments	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Year</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,598</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2028 and after</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">72,236</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">73,850</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q4	bicx	Capital Lease Future Minimum Payments Receivable Due In Rolling Year Two CapitalLeaseFutureMinimumPaymentsReceivableDueInRollingYearTwo	0	usd
CY2022Q4	bicx	Capital Lease Future Minimum Payments Due Current CapitalLeaseFutureMinimumPaymentsDueCurrent	0	usd
CY2022Q4	bicx	Capital Lease Future Minimum Payments Receivable Due In Rolling Year Three CapitalLeaseFutureMinimumPaymentsReceivableDueInRollingYearThree	0	usd
CY2022Q4	bicx	Capital Lease Future Minimum Payments Receivable Due In Rolling Year Four CapitalLeaseFutureMinimumPaymentsReceivableDueInRollingYearFour	16	usd
CY2022Q4	bicx	Capital Lease Future Minimum Payments Receivable Due In Rolling Year Five CapitalLeaseFutureMinimumPaymentsReceivableDueInRollingYearFive	1598	usd
CY2022Q4	bicx	Capital Lease Future Minimum Payments Receivable Due In Rolling After Year Five CapitalLeaseFutureMinimumPaymentsReceivableDueInRollingAfterYearFive	72236	usd
CY2022Q4	bicx	Capital Lease Future Minimum Payments Receivable CapitalLeaseFutureMinimumPaymentsReceivable	73850	usd
CY2022	bicx	Royalty Agreements Description RoyaltyAgreementsDescription	Each party would purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay each (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”).
CY2022	bicx	Expected Life Of Arrangement ExpectedLifeOfArrangement	P15Y
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	7171200	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	477436	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	477436	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	600000	shares
CY2022	bicx	Promissory Notes Aggregate Shares PromissoryNotesAggregateShares	485220	shares
CY2022	bicx	Promissory Notes Aggregate Value PromissoryNotesAggregateValue	1062632	usd
CY2022	bicx	Loss On Settlement On Debt LossOnSettlementOnDebt	198939	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7718636	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6698968	shares
CY2022	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.0000	pure
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	828631	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.84
CY2021	bicx	Outstanding Beginning OutstandingBeginning	P5Y9M18D
CY2021	bicx	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod	-13280	shares
CY2021	bicx	Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice	7.15
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	815351	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.85
CY2022	bicx	Outstanding Beginning OutstandingBeginning	P4Y10M24D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	795115	usd
CY2022	bicx	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod	350	shares
CY2022	bicx	Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice	1.60
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	59057	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.07
CY2022	bicx	Sharebased Compensation Arrangement By Sharebased Payment Grant In Period SharebasedCompensationArrangementBySharebasedPaymentGrantInPeriod	P4Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	874058	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.53
CY2022	bicx	Outstanding At Ending OutstandingAtEnding	P3Y10M24D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	559	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	866766	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.55
CY2022	bicx	Exercisable At End Of Year ExercisableAtEndOfYear	P3Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	559	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.975
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	111079	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8715	usd
CY2022	bicx	Stock Compensation Expense Unamortized StockCompensationExpenseUnamortized	13269	usd
CY2022	bicx	Weighted Average Remaining Life WeightedAverageRemainingLife	P17M
CY2022	bicx	Purchase Of Common Stock Shares PurchaseOfCommonStockShares	48309	shares
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	86821	usd
CY2022	bicx	Schedule Of Assumptions In Warrants Under Black Scholes Option Pricing Model ScheduleOfAssumptionsInWarrantsUnderBlackScholesOptionPricingModel	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.94</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected term (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">139.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2019Q2	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	6000000	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	1077088	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	1014892	usd
CY2022	bicx	Stock Issued During Period Share Issued For Service StockIssuedDuringPeriodShareIssuedForService	56345	shares
CY2021	bicx	Stock Issued During Period Share Issued For Service StockIssuedDuringPeriodShareIssuedForService	31392	shares
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	bicx	Non Controlling Interest Beginning Balance NonControllingInterestBeginningBalance	-117838	usd
CY2022	bicx	Net Loss Attributable To The Non Controlling Interest NetLossAttributableToTheNonControllingInterest	-7419	usd
CY2022	bicx	Non Controlling Interest Ending Balance NonControllingInterestEndingBalance	-125257	usd
CY2021	bicx	Non Controlling Interest Beginning Balance NonControllingInterestBeginningBalance	-115454	usd
CY2021	bicx	Net Loss Attributable To The Non Controlling Interest NetLossAttributableToTheNonControllingInterest	-2384	usd
CY2021	bicx	Non Controlling Interest Ending Balance NonControllingInterestEndingBalance	-117838	usd
CY2022Q1	bicx	Consideration Amount ConsiderationAmount	657640	usd
CY2022Q1	bicx	First Payment Owed FirstPaymentOwed	145000	usd
CY2022	bicx	First Payment Owed FirstPaymentOwed	70138	usd
CY2022	bicx	Consideration Amount ConsiderationAmount	393776	usd
CY2022	bicx	Compensation For Services Descriptions CompensationForServicesDescriptions	As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month
CY2022	us-gaap	Reductions In Other Assets Amount ReductionsInOtherAssetsAmount	6000	usd
CY2022Q4	bicx	Stock Options Grant StockOptionsGrant	10000	shares
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18946	usd
CY2022	bicx	Attorneys Fees AttorneysFees	235886	usd
CY2022	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.10	pure
CY2022	bicx	Recognized Gain Loss On Contingency RecognizedGainLossOnContingency	-322000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	bicx	Totaldeferred Benefit TotaldeferredBenefit	0	usd
CY2021	bicx	Totaldeferred Benefit TotaldeferredBenefit	0	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	bicx	Schedule Of Different Tax Rate ScheduleOfDifferentTaxRate	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Provision at statutory rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">State taxes, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.56</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.98</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.02 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8.80 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nondeductible and other items</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3.27 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(22.27 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(19.17 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr></tbody></table>
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0556	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0698	pure
CY2022	bicx	Other Increase Decrease OtherIncreaseDecrease	-0.0102	pure
CY2021	bicx	Other Increase Decrease OtherIncreaseDecrease	-0.0880	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.0327	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.0001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2227	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1917	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0000	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0000	pure
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7598	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7598	usd
CY2022Q4	bicx	Stock Options Issued For Services StockOptionsIssuedForServices	1988251	usd
CY2021Q4	bicx	Stock Options Issued For Services StockOptionsIssuedForServices	1889047	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7653663	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7505674	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	367568	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10698533	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9803675	usd
CY2022Q4	bicx	Royalty Obligation RoyaltyObligation	-306334	usd
CY2021Q4	bicx	Royalty Obligation RoyaltyObligation	-439938	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-55447	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	361781	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	439938	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	10336752	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	9363737	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10336752	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9363737	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10336752	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9363737	usd
CY2022	bicx	Federal Net Operating Losses Carryforward Description FederalNetOperatingLossesCarryforwardDescription	As of December 31, 2022, the Company had federal net operating loss carryforwards of approximately $21.9 million, of which $9.3 million, if not utilized, expire by 2029
CY2022	bicx	Cumulative Change In Ownership CumulativeChangeInOwnership	0.50	pure

Files In Submission

Name	View Source	Status
0001477932-23-002039-index-headers.html	Edgar Link	pending
0001477932-23-002039-index.html	Edgar Link	pending
0001477932-23-002039.txt	Edgar Link	pending
0001477932-23-002039-xbrl.zip	Edgar Link	pending
bicx-20221231.xsd	Edgar Link	pending
bicx-20221231_cal.xml	Edgar Link	unprocessable
bicx_10k.htm	Edgar Link	pending
bicx_ex1015.htm	Edgar Link	pending
bicx_ex311.htm	Edgar Link	pending
bicx_ex312.htm	Edgar Link	pending
bicx_ex321.htm	Edgar Link	pending
bicx_ex322.htm	Edgar Link	pending
bicx_ex43.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
bicx_10k_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bicx-20221231_pre.xml	Edgar Link	unprocessable
bicx-20221231_lab.xml	Edgar Link	unprocessable
bicx-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BICX
BioCorRx Inc. Stock $bicx

2023 Q1 Form 10-K Financial Statement

#000147793223002039 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BICX BioCorRx Inc. Stock $bicx

2023 Q1 Form 10-K Financial Statement

#000147793223002039 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BICX
BioCorRx Inc. Stock $bicx